Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early immune events in scleroderma.

A E Postlethwaite1

  • 1University of Tennessee, Memphis.

Rheumatic Diseases Clinics of North America
|February 1, 1990
PubMed
Summary
This summary is machine-generated.

Early scleroderma (systemic sclerosis) involves immune system abnormalities, including autoantibodies and T-cell defects, driving disease processes. Further research should explore fibroblast activity and the initial autoimmune triggers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic exposure of interleukin-13 suppress the induction of matrix metalloproteinase-1 by tumour necrosis factor α in normal and scleroderma dermal fibroblasts through protein kinase B/Akt.

Clinical and experimental immunology·2017
Same author

Handling missing data issues in clinical trials for rheumatic diseases.

Contemporary clinical trials·2010
Same author

Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma).

Clinical and experimental immunology·2010
Same author

Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles.

Clinical and experimental immunology·2006
Same author

Juvenile arthritis and autoimmunity to type II collagen.

Arthritis and rheumatism·2001
Same author

Can we induce tolerance in rheumatoid arthritis?

Current rheumatology reports·2001
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Area of Science:

  • Immunology
  • Rheumatology
  • Autoimmune Diseases

Background:

  • Scleroderma (systemic sclerosis) is characterized by immune system dysregulation.
  • Early stages exhibit both humoral and cellular immune abnormalities.

Purpose of the Study:

  • To summarize the immune abnormalities in early scleroderma.
  • To highlight the role of autoimmune reactions and immunoregulation defects.
  • To suggest future research directions.

Main Methods:

  • Review of existing literature on immune responses in scleroderma.
  • Analysis of autoantibodies, cytokines, and cellular immune markers.
  • Identification of potential research gaps.

Main Results:

Related Experiment Videos

  • Patients show diverse autoantibodies and evidence of impaired immunoregulation.
  • Excessive helper T-cell activity is implicated.
  • Elevated cytokines and interleukin-2 receptors indicate active cellular immunity.

Conclusions:

  • Ongoing autoimmune reactions, driven by cellular and humoral immune abnormalities, contribute to scleroderma pathogenesis.
  • Future research should investigate fibroblast autonomy and the initial autoimmune stimulus.